• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 5 Health Care Stocks That Are Ticking Portfolio Bombs

    3/14/23 8:45:46 AM ET
    $AMYT
    $CSII
    $IMRX
    $PRVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AMYT alert in real time by email

    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

    The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70.

    Here’s the latest list of major overbought players in this sector.

    Immuneering Corporation (NASDAQ:IMRX)

    • Immuneering posted a narrower-than-expected quarterly loss. “2022 was a year of important progress towards our goal of creating impactful new medicines for cancer patients,” said Ben Zeskind, Ph.D., MBA, Co-founder, and Chief Executive Officer of Immuneering. The company’s stock has a 52-week high of $16.17 .
    • RSI Value: 75.04
    • IMRX Price Action: Shares of Immuneering gained 6.2% to close at $8.00 on Monday.

    Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

    • Protagonist Therapeutics announced JNJ-2113 met its primary endpoint in the Phase 2b FRONTIER 1 clinical trial in psoriasis. The company’s stock has a 52-week high of $27.41.
    • RSI Value: 80.33
    • PTGX Price Action: Shares of Protagonist Therapeutics rose 1.5% to close at $25.38 on Monday.

    Provention Bio, Inc. (NASDAQ:PRVB)

    • Sanofi announced plans to acquire Provention Bio. The company has a 52-week high of $24.23.
    • RSI Value: 86.36
    • PRVB Price Action: Shares of Provention Bio gained 259.7% to close at $24.10 on Monday.

    Cardiovascular Systems, Inc. (NASDAQ:CSII)

    • Cardiovascular Systems announced a definitive agreement for Abbott to acquire the company for $20 per share. The company’s 52-week high is $23.47.
    • RSI Value: 72.14
    • CSII Price Action: Shares of Cardiovascular Systems rose 0.4% to close at $19.66 on Monday.

    Amryt Pharma plc (NASDAQ:AMYT)

    • Chiesi Farmaceutici announced it will acquire Amryt Pharma for $14.50 per ADS plus contingent value rights of up to an additional $2.50 per ADS. The company has a 52-week high of $14.77.
    • RSI Value: 71.27
    • AMYT Price Action: Shares of Amryt Pharma fell 0.4% to settle at $14.55 on Monday.

    Read More: These 3 Industrials Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

    Get the next $AMYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMYT
    $CSII
    $IMRX
    $PRVB

    CompanyDatePrice TargetRatingAnalyst
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    Protagonist Therapeutics Inc.
    $PTGX
    9/17/2025$72.00Overweight
    Barclays
    Protagonist Therapeutics Inc.
    $PTGX
    9/12/2025$73.00Outperform
    Leerink Partners
    Protagonist Therapeutics Inc.
    $PTGX
    6/17/2025$72.00Buy
    Citigroup
    Immuneering Corporation
    $IMRX
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$47.00Neutral
    Goldman
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$62.00Outperform
    BMO Capital Markets
    Protagonist Therapeutics Inc.
    $PTGX
    11/5/2024$58.00Outperform
    Wedbush
    More analyst ratings

    $AMYT
    $CSII
    $IMRX
    $PRVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TZIELD issued to PROVENTION BIO INC

    Submission status for PROVENTION BIO INC's drug TZIELD (ORIG-1) with active ingredient TEPLIZUMAB-MZWV has changed to 'Approval' on 11/17/2022. Application Category: BLA, Application Number: 761183, Application Classification:

    11/21/22 12:03:06 AM ET
    $PRVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Immuneering with a new price target

    Leerink Partners initiated coverage of Immuneering with a rating of Outperform and set a new price target of $15.00

    10/31/25 8:20:02 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Protagonist Therapeutics with a new price target

    Barclays initiated coverage of Protagonist Therapeutics with a rating of Overweight and set a new price target of $72.00

    9/17/25 8:03:08 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Protagonist Therapeutics with a new price target

    Leerink Partners initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $73.00

    9/12/25 7:52:34 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    - 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 - - On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 - - Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 - - Ended 2025 with $217 million in cash, cash equivalents and marketable s

    3/6/26 7:45:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Present at the Leerink Global Healthcare Conference

    NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerink Global Healthcare Conference, taking place in Miami, Florida, from March 9-11, 2026. Ben Zeskind, Chief Executive Officer, will discuss the company's pipeline, platform, and business strategy. Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, March 9, 2026, from 3:40 – 4:10 pm ET The presentation will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneerin

    3/2/26 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

    Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE Studies Prescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year Takeda ((TAK) and Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted

    3/2/26 2:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Lewis T exercised 18,000 shares at a strike of $10.84 and sold $1,483,560 worth of shares (18,000 units at $82.42) (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    2/18/26 6:12:56 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Waddill William D. exercised 20,000 shares at a strike of $8.31 and sold $1,673,600 worth of shares (20,000 units at $83.68) (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    2/6/26 4:38:54 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF LEGAL OFFICER, SECRETARY Bookman Michael

    4 - Immuneering Corp (0001790340) (Issuer)

    2/5/26 8:44:51 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    SEC Filings

    View All

    SEC Form 10-K filed by Immuneering Corporation

    10-K - Immuneering Corp (0001790340) (Filer)

    3/6/26 8:29:06 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Immuneering Corp (0001790340) (Filer)

    3/6/26 8:09:20 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Protagonist Therapeutics Inc.

    S-8 - Protagonist Therapeutics, Inc (0001377121) (Filer)

    2/25/26 4:36:51 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    Financials

    Live finance-specific insights

    View All

    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping

    1/7/26 4:00:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

    NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. "We are excited to share updated overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients," said Ben Zeskind, Ph.D

    12/23/25 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

    - New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financial results and trial investigators will provide case studies from first-line pancreatic cancer patients treated in the company's Phase 2a study of atebimetinib in combination with FOLFIRINOX, on Wednesday, November 12, 2025, after th

    11/4/25 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

    SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    11/14/24 4:27:37 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 4:15:35 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CSII
    $IMRX
    $PRVB
    Leadership Updates

    Live Leadership Updates

    View All

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

    Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,

    7/31/24 9:15:00 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist Therapeutics Set to Join S&P SmallCap 600

    NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a

    6/27/24 5:44:00 PM ET
    $PTGX
    $SPGI
    $WIRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance